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Abstract
A murine model of delayed-type hypersensitivity (DTH) is characterized with respect to liposome accumulation at a site of
inflammation. Mice were sensitized by painting the abdominal region with a solution of 2,4-dinitrofluorobenzene (DNFB)
and inflammation was induced 5 days later by challenging the ear with a dilute solution of DNFB. The inflammatory
response was readily monitored by measuring ear thickness (edema) and radiolabeled leukocyte infiltration. Maximum ear
swelling and cellular infiltration occurred 24 h after the epicutaneous challenge with the ear returning to normal size after
approximately 72 h. We demonstrate that large unilamellar vesicles (LUV) accumulate at the site of inflammation to a level
more than 20-fold higher than that measured in the untreated ear. Vesicle delivery to the ear correlated with increased
vascular leakage resulting from endothelium remodeling in response to DNFB challenge, and was not a consequence of
increased local tissue blood volume. Extravasation occurred only during the first 24 h after ear challenge; after this time the
permeability of the endothelium to vesicles returned to normal. We further showed that LUV with a diameter of 120 nm
exhibit maximum levels of accumulation, that a polyethylene glycol surface coating does not increase delivery, and that the
process can be inhibited by the application of topical corticosteroids at the time of induction. These data and the
inflammation model are discussed with respect to developing lipid-based drug delivery vehicles designed to accumulate at
inflammatory disease sites. ß 1999 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The accumulation of liposomal drug delivery sys-
tems within tumors and sites of in£ammation or in-
fection is well documented. This phenomenon of dis-
ease-site targeting is believed to play a major role in
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the enhanced e⁄cacy observed for a variety of drugs
when formulated inside lipid vesicles [1^4]. Lipid-
based formulations of the anthracyclines daunomy-
cin and doxorubicin [4,5] have been in clinical use for
several years now, and exhibit markedly improved
therapeutic pro¢les over the free drug. A more recent
example is vincristine, a vinca alkaloid commonly
used to treat lymphatic malignancies, which exhibits
dramatically enhanced e⁄cacy and modestly reduced
toxicity when administered in sphingomyelin/choles-
terol large unilamellar vesicles (LUV) [6,7]. In gener-
al, the pharmacodynamics of liposomal drug delivery
to tumors in animal models is well characterized [8^
14]; however, less is known about the extravasation
of lipid vesicles into areas of in£ammation.
In this study we have characterized a murine mod-
el of in£ammation with respect to liposome accumu-
lation that is based on a delayed-type hypersensitiv-
ity (DTH) response to cutaneous contact with the
chemical irritant, 2,4-dinitro£uorobenzene (DNFB)
[15,16]. As DNFB di¡uses across the stratum cor-
neum and into the epidermis, it reacts with amino
acid side chains of cell surface proteins. These hap-
ten-modi¢ed self proteins are processed by antigen-
presenting cells resident in the skin, primarily Lan-
gerhans cells and to some extent epidermal keratino-
cytes. The Langerhans cells migrate from the epider-
mis via the dermal lymphatic vessels to regional
lymph nodes where they mature into interdigitating
dendritic cells, which express high levels of MHC
class II molecules. These specialized antigen-present-
ing cells stimulate naive T-cells (CD4) to di¡eren-
tiate into e¡ector and memory lymphocytes, which
circulate through the blood and peripheral tissues. A
second cutaneous exposure to DNFB stimulates
hapten-speci¢c T-lymphocytes residing in the dermis
to release proin£ammatory cytokines, initiating a lo-
calized in£ammatory response at the challenge site.
A cascade of events then occurs, resulting in a tem-
porary remodeling of the local dermal vasculature
that allows leakage of macromolecules and extrava-
sation of cells into the peripheral tissue. These in-
£ammatory events can generally be measured in
terms of four basic endpoints: erythema (redness),
edema (swelling), vascular leak (of proteins and small
molecules), and cellular in¢ltration (neutrophils,
monocytes, and T cells) [15^17].
One of the primary in£ammatory events initiated
by the second DNFB exposure is an increased ex-
pression of intercellular adhesion molecule-1
(ICAM-1) on the luminal surface of local endothelial
cells, keratinocytes, and antigen-presenting cells in
the dermis. This protein assists in antigen presenta-
tion to T lymphocytes and enhances leukocyte traf-
¢cking to the in£ammation site by binding circulat-
ing leukocytes to the walls of local blood vessels [18].
Diapedesis and migration of leukocytes into the ex-
travascular tissue follow, and it is at this phase of the
in£ammatory process that lipid vesicles would be ex-
pected to extravasate. This model provides a rapid
and useful tool to investigate and optimize liposomal
formulations with respect to extravasation and dis-
ease-site accumulation. Furthermore, we intend to
employ this model to evaluate the delivery and e⁄-
cacy of liposomal formulations of novel anti-in£am-
matory therapeutics, including antisense oligonucleo-
tides and plasmids.
2. Materials and methods
2.1. Chemicals and lipids
Distearylphosphatidylcholine (DSPC) and egg
phosphatidylcholine (EPC) were purchased from
Avanti Polar Lipids (Pelham, AL, USA). Cholesterol
(CH), dexamethasone, and 2,4-dinitro£uorobenzene
(DNFB) were purchased from Sigma (St. Louis,
MO, USA). 1-O-(2P-(g-methoxypolyethyleneglycol)-
succinoyl)-2-N-arachidoylsphingosine (PEG-CerC20)
was kindly synthesized by Dr. Zhao Wang (Inex
Pharmaceuticals, Burnaby, B.C., Canada). [14C]-
and [3H]cholesterylhexadecylether (CHE), [3H]methyl
thymidine, and the tissue solubilizer Solvable were
obtained from Dupont NEN (Boston, MA, USA).
All reagents were used without further puri¢ca-
tion.
2.2. Mice
Female 8-week-old (25 g) ICR mice were obtained
from Harlan Sprague^Dawley and quarantined for
1 week prior to use. Each experimental group con-
sisted of at least four mice.
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2.3. Sensitization and initiation of in£ammation
The abdominal region of ICR mice was shaved
using an electric razor. Mice were sensitized by ap-
plying 25 Wl of 0.5% DNFB in a vehicle of acetone/
olive oil (4:1, v/v) to the shaved abdominal wall for
two consecutive days [15]. Four days after the second
application, mice were lightly anesthetized with a gas
inhalant (halothane) before being challenged on the
dorsal surface of the left ear with 10 Wl of 0.2%
DNFB in the same vehicle. Mice received no treat-
ment on the right ear. In some cases control mice
received 10 Wl of vehicle on the dorsal surface of
the left ear.
2.4. Evaluation of ear swelling
Baseline ear thickness measurements were ob-
tained on anesthetized mice immediately prior to
DNFB ear challenge. Thickness measurements were
made using an engineer’s micrometer (Mitutoyo, To-
kyo, Japan), with care being taken to measure only
the outer two-thirds of the ear, avoiding skin folds
located at the base. Measurements were taken in
quadruplicate and the thickness expressed as the
mean þ standard deviation. At various time intervals
after ears were challenged with DNFB, mice were re-
anesthetized and their ear thickness was measured.
Care was taken not to overly compress the swollen
ear between each of the quadruplicate measurements.
The average increase in ear thickness was determined
by subtracting the baseline measurements from post-
challenge measurements.
2.5. Evaluation of cellular in¢ltration
All mice received a 500 Wl intraperitoneal (i.p.)
injection of [3H]methyl thymidine in sterile saline
(1 WCi/g of body weight) 24 h before the ear was
painted with DNFB [19]. After ear thickness meas-
urements were recorded, ears were excised above the
major ear fold. Ear tissue was digested whole in
500 Wl of Solvable for 12^48 h at 60‡C. Samples
were then decolorized as described by Longman
et al. [10] and analyzed for radiolabeled leuko-
cytes by standard liquid scintillation counting. A
relative estimate of cellular in¢ltration was deter-
mined by expressing the ratio of the radioactiv-
ity observed in the in£amed versus nonin£amed
ears.
2.6. Evaluation of liposome accumulation
Large unilamellar vesicles (LUV) composed of
DSPC/CH (55:45 molar ratio) or DSPC/CH/PEG-
CerC20 (45:45:10) were prepared in Hepes-bu¡ered
saline (20 mM Hepes, 145 mM NaCl, pH 7.4) by
extrusion through two stacked polycarbonate ¢lters
of de¢ned pore sizes, as described by Hope et al. [20].
Filter pore sizes were typically 100 nm in diameter
unless otherwise indicated. Small unilamellar vesicles
(SUV) composed of DSPC/CH (55:45) were pre-
pared by probe sonication using a Branson microtip
soni¢er. Vesicle sizes were determined by quasi-elas-
tic light scattering (QELS) using a Nicomp Model
370 submicron particle sizer (Paci¢c Scienti¢c, Santa
Barbara, CA, USA). All liposome preparations con-
tained the nonexchangeable lipid marker [14C]- or
[3H]CHE. Vesicles were administered at a dose of
100 mg/kg (200 Wl ; V2 WCi of CHE per mouse)
via the lateral tail vein after initiation of ear in£am-
mation. At various times, mice were anesthetized
with ketamine/xylazine [9] and blood was collected
by cardiac puncture. Ear pinna were collected from
just above the major ear fold. Plasma was obtained
and analyzed for radioactivity using liquid scintilla-
tion techniques [9,10]. Ear tissue was digested in
Solvable for 12^48 h at 60‡C, as described above,
and subsequently decolorized before liquid scintilla-
tion counting to determine the amount of radiola-
beled lipid marker accumulation.
2.7. Corticosteroids
Two corticosteroid preparations were tested as
positive controls for reducing murine ear in£amma-
tion. Mice received a 50 Wg/ear dose of dexametha-
sone (Sigma) dissolved in acetone/olive oil (4:1, v/v).
Dexamethasone was applied topically to the dorsal
surface of the in£amed ear with a pipette 20 min
after the ear was challenged with DNFB. Alterna-
tively, mice were treated with Ultravate (active ingre-
dient: halobetasol propionate, 0.05%, w/w), which
was kindly donated by Dr. N. Kitson, Division of
Dermatology, University of British Columbia. Ultra-
vate, in the form of a gel, was spread evenly over the
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entire dorsal surface of the target ear 20 min after
DNFB challenge. To determine the e¡ect of cortico-
steroids on LUV accumulation, mice received a lat-
eral tail vein injection of 100 nm DSPC/CH (55:45)
LUV, at a dose of 100 mg/kg, 15 min after cortico-
steroid application to the ears. At appropriate times
mice were terminated and ears removed for scintilla-
tion counting as described above.
3. Results
3.1. Evaluation of ear in£ammation
The most straightforward measurement used to
monitor the progression of in£ammation in this
model is ear thickness, which re£ects the presence
of edema [15,17]. In ICR mice, an increase in ear
thickness is measurable 6 h after DNFB challenge;
it peaks at 24 h and essentially returns to normal
levels after 72 h (Fig. 1, solid circles). We found
this measurement to be highly reproducible as long
as the protocol outlined in Section 2 is adhered to.
The pinnae of untreated ears exhibited an average
baseline thickness of 21 Wm. At the peak of in£am-
mation this approximately doubled to 40 Wm, con-
sistent with what has been reported previously
[21]. Increases in thickness were not observed for
control ears that received vehicle alone (data not
shown).
The in£ammatory process was also evaluated by
measuring cell tra⁄cking into the treated ear relative
to the contralateral control. Bone marrow cells and
circulating lymphocytes were labeled with [3H]methyl
thymidine as described in Section 2. Predominantly
neutrophils, monocytes, and T lymphocytes begin to
accumulate after a lag period of 6 h. As shown in
Fig. 1 (open circles), maximum cellular in£ux occurs
at 24 h, the same as for maximum ear thickness but
in¢ltration levels decay more slowly than the swel-
ling. In a similar model, Goebler et al. [22] demon-
strated that the total number of in¢ltrating cells
measured by histochemical techniques also peaked
at 24 h but these cells did not completely leave the
in£ammation site for about 2 weeks.
3.2. Liposome accumulation at the in£ammation site
Large unilamellar vesicles (LUV), composed of
DSPC/CH and with a diameter of approximately
120 nm, were used to assess liposome extravasation
and accumulation at the in£ammation site. This type
of LUV is known to be stable in blood and, at a dose
of approximately 100 mg/kg, exhibits a relatively
long circulation half-life in mice (Fig. 2A). However,
by 24 h approximately 90% of the initial lipid dose
has been cleared from the blood. A net extravasation
of vesicles into treated but not untreated ears is ob-
served during the plasma elimination phase. Vesicles
administered as an i.v. bolus injection via the lateral
tail vein immediately after the epicutaneous applica-
tion of DNFB accumulated over the ¢rst 24 h (Fig.
2B, solid squares). The increase and subsequent de-
cline in vesicle concentration at the in£amed site re-
£ects the kinetics observed for changes in ear thick-
ness and cellular in¢ltration (Fig. 1), peaking at 24 h
but, like the thickness measurement, returning to
near background levels by 72 h.
To measure the relative permeability of the vascu-
lature to LUV during the time course of in£amma-
Fig. 1. Time course for ear thickness and cellular in¢ltration
following a DNFB challenge. Mice were sensitized as described
in Section 2. Three days later they were given an intraperitoneal
(i.p.) injection of [3H]methyl thymidine. Baseline ear measure-
ments were made 24 h later, using an engineer’s micrometer.
Mice were subsequently challenged on the dorsal surface of the
left ear with a 0.2% DNFB solution to initiate in£ammation.
At the times indicated, ear thickness (b) was measured and ex-
pressed as a percent increase over the baseline value. The mice
were killed and the level of 3H-labeled leukocytes measured in
each ear. Cellular in¢ltration (a) is expressed as the ratio of
radioactivity measured in the in£amed ear to the activity in
the contralateral, control ear. Data are expressed as the mean
þ S.D., n = 4 animals.
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tion, vesicles were administered to separate groups of
animals either at the time of challenge with DNFB
(t = 0), or at 24 or 48 h post-challenge. The level of
radioactivity accumulated in the ears was measured
24 h later. The data (Fig. 3) show that for this acute
in£ammation response, lipid accumulation in the in-
£amed ears occurred only during the ¢rst 24 h. The
concentration of LUV in the circulation is the same
for all three 24 h periods (0^24; 24^48; 48^72), but
vesicles administered at 24 and 48 h post-challenge
do not accumulate to any signi¢cant extent in treated
ears and not at all in the control ears.
When determining liposome accumulation in an
organ or at a tissue site, corrections must be made
for blood volume. This is because the level of vesicles
remaining in the blood pool can make a signi¢cant
contribution to the total level of liposomal lipid
measured in a tissue. In the experiments described
here, vasodilation was present because erythema
was observed almost immediately after DNFB chal-
lenge and only gradually declined in intensity over
the 72 h in£ammation time course. Vesicle radioac-
tivity was hardly detectable in the plasma at 24 h
(Fig. 2A), and therefore was not expected to contrib-
ute to the overall level of lipid measured in the ears
at this time point. However, the following experi-
ment was conducted to rule out this possibility.
The same dose of vesicles given immediately after
ear challenge (t = 0 h) was instead given 24 h after
ear challenge (t = 24 h) and radioactivity in the ears
was determined 2 min later. At 100 mg/kg and early
time points, DSPC/CH LUV can be employed as a
blood volume marker [23]. The data showed that the
lipid contribution resulting from blood in the in-
£amed ears at 24 h was indistinguishable from that
measured for the contralateral control ears (data not
shown), and was approximately 20-fold less than the
lipid accumulation measured in the in£amed ear dur-
ing the initial 24 h interval of ear in£ammation.
Fig. 3. Permeability of the vasculature to LUV during three 24
h intervals following DNFB ear challenge. Sensitized mice were
challenged on the left ear with DNFB. Radiolabeled LUV (120
nm, 100 mg/kg) were administered by lateral tail vein injection
at di¡erent stages of in£ammation. One set of mice received an
LUV injection immediately after ear challenge (t = 0 h), another
set received LUV 24 h after ear challenge (t = 24 h), while the
last group were administered LUV 48 h post-ear painting
(t = 48 h). Liposomes were allowed to circulate for 24 h, after
which time DNFB-treated ears (solid bars) and nontreated ears
(open bars) were removed, digested, and analyzed for lipid ac-
cumulation (see Section 2). Data are expressed as the
mean þ S.D., n = 4 animals.
Fig. 2. The clearance of LUV from the circulation (A) and
their concomitant accumulation in the in£amed ear (B). Fifteen
minutes after DNFB ear challenge, mice were injected with ra-
diolabeled vesicles, 120 nm in diameter and composed of
DSPC/CH (55:45), at a dose of 100 mg/kg. At the times indi-
cated, mice were killed and blood removed to determine the
vesicle concentration remaining in plasma; data are shown in
panel A (b). In£amed (F) and nonin£amed (E) ears were also
removed and analyzed for lipid content (panel B). Data are ex-
pressed as the mean þ S.D., n = 4 animals.
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3.3. E¡ect of topical corticosteroids
Corticosteroids are known to inhibit cellular in¢l-
tration and edema in this in£ammation model [15^
17]. We therefore measured their e¡ect on lipid ac-
cumulation in the target tissue. Two di¡erent cortico-
steroids were employed in these studies, and both
exhibited the same e¡ects. Drugs were applied
20 min after the ear was challenged with DNFB to
allow the contact irritant su⁄cient time to di¡use
into the skin. Dexamethasone was dissolved in a ve-
hicle of acetone and olive oil (4:1, v/v) at a concen-
tration of 5 mg/ml, and a 10 Wl dose was applied to
the dorsal surface of the mouse ear using a pipette.
The second drug was a commercially available gel
containing 0.05% (w/w) halobetasol propionate
(HBP), which was spread evenly over the ear. Both
drugs e¡ectively inhibited the increase in ear thick-
ness and signi¢cantly reduced cellular in¢ltration and
lipid accumulation (Fig. 4).
3.4. E¡ect of vesicle size and plasma concentration on
extravasation
To determine what features are important for
maximizing vesicle accumulation at the in£ammation
site, several physical parameters were examined. Ra-
diolabeled liposomes composed of DSPC/CH (55:45)
or DSPC/CH/PEG-CerC20 (45:45:10) and having
mean diameters of 120, 230, and 450 nm were gen-
erated using the extrusion technique [20]. Sonication
of DSPC/CH LUV resulted in vesicle diameters aver-
aging 60 nm; DSPC/CH/PEG-PegC20 SUV were not
evaluated since, in the presence of 10 mol% PEG-
lipid, it was di⁄cult to produce vesicles with diame-
ters less then 100 nm using the sonication procedure.
These were administered immediately following
DNFB ear challenge at a dose of 100 mg/kg and
after 24 h the extent of lipid accumulation in the
ears was measured (Fig. 5B). Additionally, the clear-
ance kinetics of the di¡erent vesicles were examined
during the 24 h period (Fig. 5A). DSPC/CH LUV
with a diameter of approximately 120 nm accumu-
lated in the in£amed ears to a level that was 2-fold
greater than that observed for either the 60 or
230 nm vesicles, and at least 4-fold greater than the
450 nm vesicles (Fig. 5B, solid bars). It has been
noted previously that vesicles with a mean diameter
of 100 nm exhibit longer circulation times than
smaller or larger vesicles with the same composition
[24], and this trend was also observed here (Fig. 5A).
These data suggest that there is a correlation between
plasma residence time and the level of vesicle accu-
Fig. 4. E¡ect of topical corticosteroids on edema (A), cellular
in¢ltration (B), and vesicle extravasation (C). Sensitized mice
were challenged with DNFB; 20 min later corticosteroids were
applied topically to the dorsal surface of the left ear, as de-
scribed in the text. Fifteen minutes after this, mice were injected
intravenously with 100 mg/kg of radiolabeled 120 nm DSPC/
CH (55:45) LUV. Increase in ear thickness was determined by
subtracting the baseline ear measurements from the 24 h post-
ear challenge measurements. Cellular in¢ltration and lipid accu-
mulation were measured as described in Section 2 and in the
text. All data are expressed as the mean þ S.D., n = 4 animals.
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mulation in the area of in£ammation. This is clearly
seen from the data in Fig. 6. When DSPC/CH LUV
(120 nm) are administered over a wide concentration
range, to vary the circulation half-life, the area under
the plasma clearance curves (plasma AUC) plotted
against the area under the curve for lipid in the in-
£amed ear (ear AUC) shows a positive correlation. It
was surprising, therefore, to observe that 120 nm
LUV coated with polyethylene glycol (PEG) accumu-
lated to a similar (perhaps lower) level than 120 nm
uncoated vesicles (Fig. 5B, solid compared to open
bars). PEG is known to inhibit the opsonization of
vesicles in the circulation and increase circulation
half-life [25], as is clearly shown in Fig. 5A (open
symbols).
4. Discussion
The accumulation of liposomes in tumors and oth-
er disease sites, such as in£ammation or infection, is
an important factor in their use as clinical agents to
enhance the activity of encapsulated chemotherapeu-
tics [2,26] or to improve the diseased/normal tissue
contrast ratio of imaging agents [27^30]. Thus,
understanding the mechanism of vesicle extravasa-
tion and the factors that govern it will enable the
design of more e¡ective drug delivery systems. Here
we have characterized the accumulation of liposomes
at an in£ammation site using a simple animal model
of DTH. The in£ammatory response was observed to
be highly reproducible and in£icted a minimal level
Fig. 6. Correlation between the plasma concentration of vesicles
and lipid accumulation in the in£amed ear. Vesicles (DSPC/CH,
120 nm diameter) were administered at doses of 50, 100, 300,
and 500 mg/kg lipid to sensitized mice 15 min after the mice
were challenged with DNFB. The concentration of vesicles in
both the plasma and ears was measured at 0, 6, 12, and 24 h.
Pro¢les of the clearance and accumulation kinetics were plotted
either as percent of initial dose remaining in the circulation
(clearance) or Wg of lipid per ear (accumulation) for the 24 h
time period (each point the mean of four mice þ S.D.). The
area under the curves (AUC) for each dose was measured and
the data plotted.
Fig. 5. The in£uence of vesicle size on plasma clearance kinetics
(A) and extravasation at the in£ammation site (B). Sensitized
mice were challenged on the left ear with DNFB. Radiolabeled
LUV composed of DSPC/CH (55:45 mol/mol, solid symbols
and bars) or DSPC/CH/PEG-CerC20 (45:45:10 mol/mol, open
symbols and bars) were prepared by extrusion through 100,
200, or 400 nm ¢lters, yielding vesicles of 120 (circles), 230
(squares), and 450 (triangles) nm in diameter, respectively. Soni-
cation was used to prepare 60 nm DSPC/CH SUV (inverted tri-
angle), while DSPC/CH/PEG-CerC20 SUV were not examined.
All vesicle preparations were administered via lateral tail vein
injection, at a dose of 100 mg/kg. At the times indicated, plas-
ma was removed and analyzed for radioactivity as described in
the Section 2. DNFB-treated ears were removed 24 h after
vesicle administration, digested, and analyzed for lipid accumu-
lation as described previously. Data are expressed as the
mean þ S.D., n = 4 animals.
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of discomfort upon the animals. Furthermore, the
development of in£ammation can be monitored us-
ing several direct quantitative measurements, includ-
ing ear thickness and leukocyte tra⁄cking.
Vesicle extravasation into tumors appears to be a
passive process in which circulating particles di¡use
through large pores in the tumor microcirculation
[31]. The hyperpermeability of the tumor vasculature
is primarily dependent on the release of vascular en-
dothelial growth factor (VEGF) by tumor cells.
VEGF is responsible for promoting angiogenesis in
the growing tumor. The creation of new blood ves-
sels requires existing vessel walls to be disrupted and
basement membranes to be dissolved. Endothelial
cells are stimulated to proliferate and migrate, form-
ing new capillary loops and branches [32]. However,
the exact nature of the pores remains unclear and is
the focus of intense research because they represent a
potential route of access for drugs used in the treat-
ment of cancer. Transport across blood vessels oc-
curs by a variety of routes, including open gaps (in-
terendothelial junctions and transendothelial
channels), caveolae, vesicular vacuolar organelles
(VVO), fenestrations, and phagocytosis. Recently,
Jain and coworkers [33] showed that liposomes ex-
travasate into subcutaneous tumors in mice via inter-
endothelial gaps, with pore sizes ranging from 0.2 to
1.2 Wm. However, the size and number of pores were
observed to be dependent upon the microenviron-
ment of the tumor, and both may be signi¢cantly
reduced during tumor regression.
In the DTH model utilized for this work, recogni-
tion of the hapten DNFB by epidermal cells causes
the release of proin£ammatory cytokines such as in-
terleukin-1L, interferon-Q, and tumor necrosis factor-
K. These molecules induce up-regulation and increase
expression of endothelial leukocyte adhesion mole-
cule-1 (ELAM-1) and intercellular adhesion mole-
cule-1 (ICAM-1) on the surface of endothelial cells
in the local microvasculature. The adhesion mole-
cules then bind circulating leukocytes to the endothe-
lium. This process results in a dramatic change in
blood vessel permeability [34] as the capillary vascu-
lature undergoes structural remodeling to allow leu-
kocyte diapedesis. Presumably, the interendothelial
cell gaps that enable leukocyte extravasation also
allow vesicle di¡usion out of the blood compartment.
This is consistent with the measured time courses for
edema formation, cellular in¢ltration, and vascular
leak as shown in Figs. 1 and 2B.
Liposomes leave the in£ammation site more
quickly than the cellular in¢ltrate. Lipid radioactivity
has returned to normal levels by 72 h, but 3H-labeled
leukocytes remain in the skin for many days [22]. As
the vascular endothelium becomes impermeable to
vesicle extravasation again 24 h after DNFB contact
(Fig. 3), vesicles cannot leak back into the circulation
the same way they entered. However, the rate at
which vesicles are cleared from the ear is similar to
the rate of decrease in edema swelling measurements
(Figs. 1 and 2B). Tissue clearance of the vesicles
probably occurs by drainage of the vesicles into the
lymphatic system along with small molecules and
£uid and/or by macrophage phagocytosis, which sim-
ilarly removes vesicles from tissue via the lymphatics.
The cellular in¢ltrate leaves the in£ammation site
more slowly than vesicles; this may re£ect the adhe-
sive interactions that leukocytes have with dermal
and epidermal cells such as keratinocytes. In this in-
£ammation model, ICAM-1 expression on keratino-
cytes has been shown to peak at around 72 h and
decay slowly during a 2-week period [22]. Further-
more, the increased expression of keratinocyte
ICAM-1 correlates with an increased localization of
T lymphocytes in the epidermis, as has been observed
in chronic in£ammatory skin disorders such as psor-
iasis [35].
If vesicle accumulation at sites of in£ammation
occurs by passive di¡usion through interendothelial
cell gaps, then the mass of lipid delivered to a partic-
ular site will be proportional to both the volume of
blood passing through the tissue per unit time and
the concentration of vesicles in the blood compart-
ment (assuming that the pore size is not limiting).
The vesicle concentration in plasma will be depend-
ent upon lipid composition, dose, and vesicle diam-
eter, as these factors in£uence the rate at which
vesicles are cleared from the circulation. The pores
are clearly large enough to allow 450 nm particles to
pass through (Fig. 5), and the di¡erence in accumu-
lation of the di¡erent-sized vesicles most likely re-
£ects their circulation half-lives. For example, LUV
with a diameter of approximately 60 nm exhibit a
larger volume of distribution in the liver than 120
nm vesicles, and as a result they tend to be cleared
from the circulation more rapidly [24,36]. Small
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vesicles have also been shown to di¡use from subcu-
taneous sites into the lymphatic system at a faster
rate than large vesicles [37]. Consequently, it is pos-
sible that the 60 nm liposomes drain from the site of
in£ammation at a faster rate than the larger ones.
The combination of these factors would be expected
to result in a lower net accumulation of 60 nm
vesicles at the in£ammation site. On the other
hand, the 230 and 450 nm systems are more readily
trapped and phagocytosed by ¢xed macrophages of
the reticuloendothelial system (RES) in the liver and
spleen. The resulting shortened circulation half-lives
for these large vesicles reduces their plasma concen-
tration more quickly, which is re£ected in the re-
duced accumulation in the in£amed ear.
It is very interesting that the PEG-coated vesicles
accumulated only to the same level measured for
PEG-free vesicles, and perhaps to even lower levels
for the 120 nm LUV, although more studies would
be necessary to ensure statistical signi¢cance. The
accumulation of the di¡erent sized PEG-coated
vesicles is similar, which is consistent with the plasma
residence times (Fig. 5A). PEG inhibits opsonization
of vesicles in plasma and slows their plasma clear-
ance by Kup¡er cells in the liver [25]. Increasing
vesicle circulation lifetimes should result in an in-
creased delivery of lipid to the in£ammation site.
However, despite a 1.6-fold increase in the AUC val-
ue (Wg lipid in plasma over 24 h, calculated from Fig.
5A) for PEG-coated compared to naked 120 nm
LUV, fewer PEG-coated vesicles accumulate. The
di¡erence is even more striking for the 450 nm lip-
osomes; in this case PEG produces a 4.3-fold in-
crease in plasma lipid AUC for the 24 h period,
yet the accumulation of vesicles is essentially the
same as for naked vesicles. Our data are similar to
the observations made in a recent study which found
that adding PEG to vesicles did not enhance their
extravasation into the peritoneal cavity, despite in-
creasing the plasma half-life by a factor of 2 [10].
When vesicles of the same size and composition
were used in the ear in£ammation model, a correla-
tion between plasma concentration and liposome ac-
cumulation at the in£ammation site was clearly seen
(Fig. 6). Taken together, these data suggest that PEG
may inhibit extravasation, an observation that war-
rants further investigation.
In conclusion, we believe that the murine model of
ear in£ammation is ideal for studying disease-site
targeting of liposomes. The in£ammation response
is fast, reproducible, well de¢ned, and easily quanti-
¢ed. The ear vasculature is hyperpermeable for the
¢rst 24 h following DNFB ear painting, during
which time particles as large as 450 nm in diameter
can extravasate into the surrounding tissue; however,
maximum lipid delivery is observed for 120 nm LUV.
Accumulation of lipid at the in£ammation site is
proportional to the plasma concentration for vesicles
of the same size and composition. We are presently
utilizing this model to investigate how lipid-based
delivery systems can enhance the activity of systemi-
cally administered anti-in£ammatory drugs.
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